Semaglutide, tirzepatide, and other GLP-1-based therapies may help appropriate patients achieve meaningful weight loss, but long-term results depend on what happens next: follow-up, strength, protein, hydration, lab monitoring, dose review, and realistic planning
economy can all be treated by treating the disease of diseases, Alexander said during Newsweeks event, and so were underestimating the cost of doing nothing, which is not zero. Not covering GLP-1s, is not a neutral financial position, either
While all three are given as once-weekly subcutaneous injections, the studied dose ranges differ considerably, reflecting differences in potency, receptor activity, and tolerability
However, the competitive landscape is rapidly evolving with next-generation molecules demonstrating superior efficacy